Between going public in 2009 and February of this year, shares of Medidata Solutions (NASDAQ: MDSO ) surged in value almost 700%. Since then, however, the stock has cooled off considerably, falling more than 40%.
Medidata has carved out a lucrative niche with drug companies. It provides cloud solutions to help companies streamline the FDA testing and approval process. While R&D costs are somewhat high right now, the company is able to win over customers and create a situation where switching costs are very high.
That business model enticed me to buy shares in August of last year. Though I have a long-term time horizon, the slideshow below will cover when any type of investor--short, medium, or long term--should be looking for when the company reports earnings later this week.
Leaked: This coming blockbuster will make every biotech jealous
Medidata isn't the only growth company in the health care sector. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.